Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ('Olema' or 'Olema Oncology', Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 10:30 a.m. ET.
A live webcast of the presentation and any accompanying materials will be available under the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording of the presentation will be made available in the same location.
About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco, California and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations ContactCourtney O'KonekVice President, Corporate CommunicationsOlema Oncologymedia@olema.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Tensions between the US and China have delayed Apple's AI rollout in China, FT reports
The Financial Times claims that the Cyberspace Administration of China (CAC) is delaying the introduction of AI services by Apple Inc. (NASDAQ:AAPL) and Alibaba in China. A wide view of an Apple store, showing the range of products the company offers. Their February deal to incorporate AI technologies into iPhones in China is on hold due to geopolitical tensions resulting from U.S. President Donald Trump's trade war. Consumer-facing AI technologies need regulatory permission, and the CAC has not yet given its approval to these applications. The business is facing diminishing iPhone sales in China due to increased local competition, particularly from Huawei, which has integrated DeepSeek's AI models into its handsets. The firm is at a disadvantage to its AI-enabled Android rivals due to its lack of sophisticated AI technologies, such as ChatGPT-powered features and Apple Inc. (NASDAQ:AAPL)'s postponed "Apple Intelligence." More pressure is added by Trump's recent pronouncement of a 25% tariff on iPhones sold in the US that are not produced locally. New software improvements are anticipated during Apple Inc. (NASDAQ:AAPL)'s WWDC event, which takes place from June 9–13. While we acknowledge the potential of AAPL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio
Business Insider
an hour ago
- Business Insider
iOThree receives Nasdaq notification regarding minimum bid price deficiency
iOThree (IOTR) Limited announced that it has received a written notification from the Nasdaq Stock Market LLC on June 3, 2025, indicating that the Company was not in compliance with the $1.00 closing bid price requirement for the last 30 consecutive business days from April 21, 2025 to June 2, 2025 under the Nasdaq Listing Rule 5550(a)(2). This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Nasdaq notification has no immediate effect on the listing of the Company's ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker 'IOTR'. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until December 1, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's ordinary shares must be at least $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. Confident Investing Starts Here:
Yahoo
an hour ago
- Yahoo
ProZenith Launches Natural Supplement Formulated for Weight Management Support
U.S.-Made Product Supports General Wellness Goals with a 60-Day Refund Policy Aurora, June 06, 2025 (GLOBE NEWSWIRE) -- ProZenith recently announced the launch of its new wellness supplement developed to assist individuals in maintaining energy, focus, and mindful appetite awareness as part of a balanced and active lifestyle. Manufactured in the United States in a facility that is FDA-registered and GMP-certified, the product is now available through official online channels. ProZenith is intended for individuals pursuing support for general weight management and overall well-being. Its formulation includes select ingredients chosen to align with healthy routines and support individuals seeking help managing non-hunger-related snacking behaviors. Each purchase of ProZenith is covered by a 60-day refund policy, reflecting the company's customer-first return assurance framework. All ProZenith supplements are manufactured without genetically modified ingredients and adhere to U.S. quality standards. Production takes place in an FDA-registered facility that complies with current Good Manufacturing Practices (cGMP). ProZenith is currently available through the company's official online platform at with multiple purchase options provided for convenience. About ProZenith ProZenith develops nutritional supplements designed to support individuals on their wellness journeys. The company emphasizes high-quality manufacturing, transparency, and customer satisfaction as it continues to expand its product offerings for health-conscious consumers. For customer support inquiries, contact:support@ Disclaimer:This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: Company: ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 Email: support@ Order Phone Support: (925) 217-7353 CONTACT: Company: ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 Email: support@ Order Phone Support: (925) 217-7353Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
